Leishmaniasis. What do we know about its chemotherapy?

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 36, Issue 1, 2000, Pages 69-96

  De Carvalho, P B ^a   Da Graca Arribas, M A ^a   Ferreira, E I ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antimonials; Chemotherapy; Leishmaniasis; Potential antileishmanial agents

Indexed keywords

8 (6 DIETHYLAMINOHEXYLAMINO) 6 METHOXY 4 METHYLQUINOLINE; ACRIDINE DERIVATIVE; ALBENDAZOLE; ALLOPURINOL; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY TARTRATE; ATOVAQUONE; CYSTEINE PROTEINASE INHIBITOR; INOSINE DERIVATIVE; KETOCONAZOLE; LEVAMISOLE; MEGLUMINE; MEGLUMINE ANTIMONATE; MEPACRINE; METRONIDAZOLE; MEVINOLIN; MILTEFOSINE; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; PHASEOLINONE; PHOSPHONIC ACID DERIVATIVE; PRIMAQUINE; STIBOGLUCONATE SODIUM; UNINDEXED DRUG; VERAPAMIL; ZINC SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL FEATURE; CONVULSION; DRUG EFFICACY; DRUG FORMULATION; FEVER; HUMAN; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIA TROPICA; LEISHMANIASIS; LIFE CYCLE; NAUSEA; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; VOMITING;

EID: 0033776375     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Leishmaniasis - New perspectives on an underappreciated opportunistic infection
2. Could infected drug-users be potential Leishmania infantum reservoirs?
3. Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs
4. The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages
5. The reemergence of visceral leishmaniasis in Brazil
6. Metronidazole treatment in a patient with AIDS and visceral leishmaniasis
7. Granulocyte-macrophage colony stimulating factor in combination with pentavalent antimony for the treatment of visceral leishmaniasis
8. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis
9. Visceral leishmaniasis: More prevalent and more problematic
10. Drug delivery system: Targeting of pentamidines to specific sites using sugar grafted liposomes
11. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters
12. A combination of sulphadiazine, trimethoprim and metronidazole or tinidazole in kala azar
13. Alterations in membrane fluidity lipid metabolism mitochondrial activity and lipophosphoglican expression in pentamidine-resistant Leishmania
14. Down-regulation of mannose receptors on macrophages after infection with Leishmania donovani
15. Effects of steroidal allenic phosphonic acid derivatives on the parasitic protists Leishmania donovani, Leishmania mexicana mexicana, and pneumocystis carinii carinii
16. Nutritional requirements of wildtype and folate transport-deficient Leishmania donovani for pterins and folates
17. Biopterin conversion to reduced folates by Leishmania donovani promastigotes
18. PTR1: A reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major
19. Chemotherapy for leishmaniasis: Biochemical mechanisms clinical efficacy and future strategies
20. Biochemistry of Pentostan resistant Leishmania
21. Human Leishmaniasis: Clinical diagnostic and chemotherapeutic developments in the last 10 years
22. Gene amplification in Leishmania
23. Structure-activity relationships of dihydrofolate reductase inhibitors
24. New mechanisms of drug-resistance in parasitic protozoa
25. Zoonoses in leishmaniasis
26. Amphotericin-B colloidal dispersion - A review of its use against systemic fungal infections and visceral leishmaniasis
27. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania infected machrophages
28. Leishmanicidas Potenciais II. Sintese de pro-farmaco da pirimetamina
29. Potential antileishmanial drugs. III. Synthesis of targeted drug of pyrimethamine
30. Leishmania donovani: In vitro culture and [H-1] NMR characterization of amastigote-like forms
31. Sugar receptor mediated drug delivery to macrophages in the therapy of experimental visceral leishmaniasis
32. New developments in the chemotherapy of leishmaniasis
33. Molecular determinants of leishmania virulence
34. Visceral leishmaniasis treated with rifampicin and cotrimoxazole
35. Anti-leishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani
36. A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya
37. Estudo comparativo entre antimoniato de meglumina, isotianato de pentamidina e sulfato de aminosidina no tratamento de lesoes cutaneas primarias causadas por Leishmania (Viannia) brasiliensis
38. Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis
39. Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection
40. Visceral leishmaniasis in a new ecological niche near a major metropolitan area of Brazil
41. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)
42. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial
43. Practical guide for the treatment of leishmaniasis
44. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B
45. Visceral leishmaniasis and AIDS
46. Cutaneous leishmaniasis due to Leishmania infantum. Case reports and literature review
47. Leishmania cysteina proteinases: Virulence factors in quest of a function
48. Treatment of kala azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days
49. Leishmaniasis
50. Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model
51. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostan) in the treatment of mucosal leishmaniasis
52. Reactive nitrogen and oxygen intermediates in patients with cutaneous leishmaniasis
53. Concurrent mucosal leishmaniasis and pulmonary tuberculosis
54. Acetogenins and other compounds from Rollinia emarginata and their antiprotozoal activities
55. GTPases in protozoan parasites: Tools for cell biology and chemotherapy
56. Leishmanicidal and trypanocidal activities of Bolivian medicinal plants
57. Plants used in the treatment of leishmanial ulcers due to Leishmania (Viannia) braziliensis in an endemic area of Bahia, Brazil
58. Antimony oxidation states in antileishmanial drugs
59. Tratamento da leishmaniose tegumentar americana com a pentamidina. Esquema em dose unica endovenosa
60. Therapy of visceral leishmaniasis due to Leishmania infantum: Experimental assessment of efficacy of AmBisome
61. Lipid formulations of amphotericin B in the treatment of experimental viscela leishmaniasis due to Leishmania infantum
62. Contribution of serological tests to the diagnosis of visceral leishmaniasis in patients infected with the human immunodeficiency virus
63. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis
64. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B
65. Experience with amphotericin B in sodium stibogluconate-unresponsive cases of visceral leishmaniasis in north Bihar
66. Biochemistry of the Leishmania species
67. Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B
68. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of treatment
69. Leishmaniasis
70. Leishmaniases of the New World: Current concepts and implications for future research
71. Visceral leishmaniasis in a child with HIV-1 infection
72. Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B
73. Synergism in vitro of lovastatin and miconazole as anti-leishmanial agents
74. Liposomal amphotericin B AmBisome
75. Recombinant interleukin 12 cures mice infected with Leishmania major
76. Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis
77. Immunotherapy for visceral leishmaniasis: Ability of factors produced during anti-leishmania responses of skin test positive adults to inhibit peripheral blood mononuclear cell activities associated with visceral leishmaniasis
78. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy
79. Preliminary serological study on canine leishmaniasis in the Alpes-Martimes Departement, France
80. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child
81. Kala-azar: Current status of experimental chemotherapy
82. Dependence of an alkyl glycol-ether monooxygenase activity upon tetrahydropterins
83. Phlebotomine vectors of the leishmaniases: A review
84. Enzymes as parasite thiol metabolism as drug targets
85. The Brazilian leishmaniasis control program
86. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV
87. Visceral leishmaniasis in patients infected with the human immunodeficiency virus
88. Metronidazole therapy for visceral leishmaniasis
89. Evolution classification and geographical distribution
90. Demographic changes and their influence on the epidemiology of the American leishmaniases
91. The American leishmaniasis: Some observations on their ecology and epidemiology
92. Epidemiology and ecology of leishmaniasis in Latin-America
93. Vaccination of c57bl/10 mice against cutaneous leishmaniasis. Use of purified GP63 encapsulated into niosomes surfactants vesicles: A novel approach
94. Epidemiology of the leishmaniases
95. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm
96. Extremely rapid endocytosis mediated by the mannose receptor of sinusoidal endothelial rat liver cells
97. Leishmaniasis in the Sudan Republic. Lack of effect of chloroquine and pyrimethamine on visceral leishmaniasis in the hamster
98. Leishmaniasis, a reemerging zoonosis
99. Leishmaniose tegumentar americana
100. Leishmaniose visceral americana (calazar americano ou neotropical.)
101. Phase 1 study of an inactivated vaccine against american tegumentary leishmaniasis in normal volunteers in Brazil
102. An experimental vaccine against American dermal leishmaniasis: Experience in the state of Espirito Santo, Brazil
103. Field trial of a vaccine against American dermal leishmaniasis
104. Activity and mode of action of acridine compounds against Leishmania donovani
105. Traitement de la leishmaniose viscerale infantile
106. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar
107. Protective effect of Picroliv from Picrorhiza kurroa against Leishmania donovani infections in Mesocricetus auratus
108. A novel antiprotozoal aminosteroid from Saracha punctata
109. Leishmania donovani: Pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo
110. Don't forget visceral leishmaniasis in transplant patients
111. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis
112. Zinc sulphate in the treatment of cutaneous leishmaniasis: An in vitro and animal study
113. New approaches to leishmania chemotherapy: Pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity
114. The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major
115. Experimental chemoterapy
116. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood
117. Antiprotozoal compounds from Asparagus africanus
118. Vectors control importance on leishmaniasis transmission
119. Treatment of american cutaneous leishmaniasis: A comparison between low dosage (5mg/kg/day) and high dosage (20mg/kg/day) antimony regimens
120. Practical progress and new drugs for changing patterns of leishmaniasis
121. Mechanisms of drug-resistance in Leishmania
122. New molecular and cellular aspects of infection by Leishmania
123. ABC transporters in Leishmania and their role in drug resistance
124. Chromosome size and number polymorphisms in Leishmania infantum suggest amplification/deletion and possible genetic exchange
125. Drug resistance in Leishmania: Similarities and differences to other organisms
126. Access to essential drugs in poor countries. A lost battle?
127. Localization of the lipophosphoglycan of Leishmania during the first steps of macrophage invasion by the parasito
128. Synthesis and biological evaluation of 4-chloro-3, 5-dinitrobenzotrifluoride analogues as antileishmanial agents
129. Destruction of intracellular and isolated Leishmania mexicana amazonensis amastigotes by amino acid amides
130. Treatment of post kala-azar dermal leishmaniasis
131. Post kala azar dermal leishmaniasis
132. The efficacy and safety of ketoconazole in visceral leishmaniasis
133. Diospyrin, a bisnaphthoquinone: A novel inhibitor of type I DNA topoisomerase of Leishmania donovani
134. Effect of levamisole on the course of experimental leishmaniasis in guinea-pigs and mice: Haematological and immunological findings
135. Serologic validation of HIV infection in a tropical area
136. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis
137. Nephrotoxicity attributed to meglumine antimoniate (glucantime) in the treatment of generalized cutaneous leishmaniasis
138. Generalized cutaneous leishmaniasis in acquired immunodeficiency syndrome
139. New antileishmanial compound, phaseolinone
140. Estudo comparativo entre o estibogluconato de sodio BP88® (Shandong Xinhua - China) e o antimoniato de meglumina (Rhodia - Brasil) no tratamento da forma cutanea de leishmaniose tegumentar americana na area endemica de Corte de Pedra Bahia Brasil
141. Um caso de leishmaniose causada por Leishmania viannia brasiliensis refrataria aos tratamentos convencionais com glucantime e pentamidina
142. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors
143. Leishmaniasis in Israel: Reservoir hosts sandfly vectors and leishmanial strains in the Negev Central Arava and along the Dead Sea
144. Effects of methotrexate and other antifolates on the growth and dihydrofolate reductase activity of Leishmania promastigotes
145. The hyperphenylalaninemias of man and mouse
146. Leishmania gene amplification - A mechanism of drug-resistance
147. Phenotypic characterization of Leishmania mexicana pentamidine-resistant promastigotes modulation of the resistance during in-vitro developmental life cycle
148. Miltefosine for visceral leishmaniasis
149. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis
150. Gold treatment for kala-azar
151. Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by 5-benzyl-2 4-diaminopyrimidines
152. The mannose receptor is a pattern recognition receptor involved in host defense
153. Oral treatment of visceral leishmaniasis with miltefosine
154. Immunochemotherapy for a systemic intracellular infection: Accelerated response using interferon-gamma in visceral leishmaniasis
155. Trial of oral miltefosine for visceral leishmaniasis
156. Effect of treatment with interferon gama alone in visceral leishmaniasis
157. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma
158. Development of a novel polymeric pro drug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration
159. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: A randomized dose finding clinical trial
160. Rationalization of regimens of treatment of kala-azar with sodium stibogluconate in India: A randomised study
161. Observations on the effect of verapamil with sodium stibogluconate in kala-azar
162. Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis
163. Synthesis and protozoocidal activities of quinones
164. Failure of albendazole as an alternative treatment of cutaneous leishmaniasis in the hamster model
165. Multidrug-resistance and P-glycoproteins inparasitic protozoa
166. Comunicado a sessao de 24 de abril de 1912 da Sociedade Brasileira de Dermatologia
167. Leishmaniose tegumentar americana
168. Canine visceral leishmaniasis: Successful chemotherapy induces macrophage anti-leishmanial activity via the L-arginine nitric oxide pathway
169. Pterin and folate reduction by the Leishmania tarentolae H locus short-chain dehydrogenase/reductase PTR1
170. Leishmania and Trypanosoma
171. DNA-based methods in the detection of Leishmania parasites: Fields applications and practicalities
172. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis
173. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniosis
174. Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis
175. Protein farnesyltransferase from Trypanosoma brucei-A heterodimer of 61- and 65-kDa subunits as a new target for antiparasite therapeutics
176. Leishmania donovani in hamsters: Stimulation of non-specific resistance by novel lipopeptides and their effect in anti-leishmanial therapy
177. The treatment of kala-azar in the Sudan with sodium stibogluconate: A randomized trial of three dosage regimens
178. The role of pH and temperature in the development of Leishmania parasites